This gene-specific epigenetic regulation parallels previous findings, where JIB-04 modulated AKT2 transcription through H3K27me3 [72], reinforcing its potential as a targeted therapeutic for MECOM-driven ovarian cancers. Here, AKT2 is linked to ovarian cancer.